The treatment options currently available in the medical therapy of advanced colorectal cancer (CRC) appear to be an abundance of riches. The integration of oxaliplatin and irinotecan as conventional cytotoxic agents as well as bevacizumab and the epidermal growth factor receptor (EGFR) antibodies, cetuximab and panitumumab, as novel targeted agents into standard medical therapy have improved median overall survival in metastatic CRC beyond 2 years. It cannot be overemphasized that these significant improvements in outcome of patients with CRC are closely linked to the number of active drugs available to treat this disease. The abundance of treatment options, however, comes with specific challenges for the practical management of palliative medical therapy in advanced CRC, in particular with regard to the utilization of targeted agents. In this context, bevacizumab has established itself as the standard component of first-line chemotherapy. It is of interest for clinical practice that so far no predictive marker for the activity of bevacizumab in metastatic CRC has been identified. The key questions surrounding the use of bevacizumab in the palliative setting are whether its continuation beyond tumor progression provides clinical benefit, and which patient group is at higher risk for bevacizumab-related toxicities. Cetuximab and panitumumab have demonstrated efficacy both in combination with chemotherapy or in contrast to bevacizumab as single agent. In unselected patients, the effect of both EGFR antibodies on time-related parameters, progression free survival and overall survival, is moderate at best with emphasis more on the induction of tumor responses in a select group of patients. Therefore, until recently, EGFR antibodies were mainly regarded as salvage therapy options, in particular, since there did not appear to be a loss of activity when used in later lines of therapy. The finding that CRC harboring KRAS (and BRAF) mutations are resistant to EGFR antibodies, has allowed us to enrich the patient population with CRC that have a chance to benefit from cetuximab or panitumumab therapy. Biomarker-based treatment decisions are therefore now an integral part of clinical practice and trial design in CRC. In conclusion, targeted agents have become an integral part of medical therapy for advanced CRC. The challenge for current oncologic practice is to develop a rationale and biomarker-based treatment algorithm utilizing all potentially active agents as individualized therapy.
Background
Colorectal cancer (CRC) affects approximately 150,000 patients in the United States every year. Among all cancers, it is the second leading cause of death in the United States, with more than 52,000 deaths annually and affecting both men and women almost equally [Jemal et al. 2008] . The prognosis for patients with stage IV disease without specific therapy is poor, with a median survival of 56 months. However, a subset of patients with isolated sites of metastases is potentially curable with surgery. Nevertheless, for the majority of patients with metastatic disease, the goal of therapy is palliation using systemic chemotherapy. For decades, standard first-line therapy consisted of fluorouracil (5-FU) plus leucovorin, with response rates of approximately 20% and a median survival of approximately 1 year. In the late 1990s and early 2000s, the addition of oxaliplatin and irinotecan to the backbone of 5-FU and leucovorin resulted in a dramatic improvement in median survival to nearly 24 months when patients received active first-and second-line therapy. Most recently, biologic agents, such as bevacizumab, cetuximab, and panitumumab, have further enhanced the efficacy of systemic medical therapy [Grothey and Marshall, 2007] .
The availability of various active agents for the treatment of metastatic CRC has resulted in an abundance of therapeutic options that now demand a goal-oriented, strategic approach to therapy to maximize patient benefit. When treating a patient with metastatic CRC, the first determination is whether a patient with stage IV disease is potentially curable by a surgical resection of metastases either at the time of diagnosis or after downsizing initially unresectable metastases by neo-adjuvant chemotherapy [Grothey and Marshall, 2007] . This will guide the choice and timing of chemotherapy because, in this scenario, the most appropriate treatment is conceivably the one that generates the highest response rate and carries the greatest potential to downsize metastases. If the patient does not appear curable, then the main goals of systemic chemotherapy are to extend the duration of a patient's life and to maintain quality of life for as long as possible. In this scenario, treatment regimens that offer the longest progression-free and overall survivals as well as a favorable toxicity profile are preferred.
Agents with proof of efficacy in colorectal cancer
Cytotoxic drugs 5-FU. For about a decade in the 1990s, the standard first-line therapy for metastatic CRC was the fluoropyrimidine analog, 5-FU, plus leucovorin (5 FU/LV) as biomodulator and activator. Leucovorin forms a complex with 5-FU that permits prolonged inhibition of the enzyme thymidylate synthase, a key factor in the DNA synthesis. Response rates of 5 FU/LV are in the range of 1525%. Over time, 5-FU has been given with leucovorin in varying schedules and doses. The most commonly used regimens in the US included the Mayo Clinic regimen (425 mg/m 2 of 5-FU and 20 mg/m 2 for leucovorin on days 1 to 5 every 4 to 5 weeks) [Poon et al. 1989] , and the Roswell-Park regimen (500 mg/m 2 of 5-FU and 500 mg/m 2 of leucovorin administered weekly for 6 out of 8 weeks) [Petrelli et al. 1989] . While these regimens used 5-FU exclusively as bolus administration, European protocols preferred to use 5-FU in the form of protracted infusions (e.g. for 46 hours in the French biweekly LV5FU2 regimen or for 24 hours in the German weekly Arbeitsgemeinschaft Internistische Onkologie regimen) [Kohne et al. 2003; De Gramont et al. 1997] . Eventually, the different 5 FU/LV regimens used in the US and Europe led to different fluoropyrimidine backbones for the addition of the newer cytotoxic agents, irinotecan and oxaliplatin. In the US, the IFL regimen was created by adding weekly irinotecan to the Roswell-Park regimen, in Europe, irinotecan and oxaliplatin were added to biweekly infusional 5 FU/LV backbones, thereby forming FOLFIRI and FOLFOX regimens. The incorporation of these novel cytotoxic agents, irinotecan and oxaliplatin, into 5-FU-based regimens resulted in significantly improved efficacy. This shifted the paradigm for front-line treatment from 5 FU/LV alone to combination regimens incorporating these newer agents.
Capecitabine. Capecitabine is an oral fluoropyrimidine, a prodrug of 5-FU, which is metabolized to its active form in three enzymatic steps. Its efficacy is similar to bolus 5-FU and leucovorin, with slightly higher response rates [Hoff et al. 2001] . Common side effects of this drug include diarrhea and handfoot syndrome. Capecitabine has been used as backbone of combination regimens with both oxaliplatin and irinotecan, but overlapping toxicities (diarrhea) make a combination with irinotecan more difficult to tolerate than oxaliplatin. While capecitabine has never been directly compared to infusional 5-FU/leucovorin, oxaliplatin-based combination regimens with either capecitabine (CAPOX or XELOX) or infusional 5 FU/LV (FOLFOX) have shown similar efficacy in the treatment of advanced CRC [Arkenau et al. 2008; Cassidy et al. 2008; Porschen et al. 2007] . It is of note, though, that patients in the United States do not tolerate the capecitabine doses used in European or Asian trials, presumably due to the higher nutritional folate intake in the US [Haller et al. 2008; Van Cutsem et al. 2000] . Reducing capecitabine dose by about 20% in combination regimens with oxaliplatin in US patients, however, does not appear to decrease the treatment efficacy, but greatly improves the side-effect profile of the treatment .
Irinotecan. The first chemotherapy agent other than 5-FU that improved survival for metastatic CRC first in second-line and then later in firstline therapy was irinotecan [Saltz et al. 2000; Cunningham et al. 1998; Rougier et al. 1998 ]. This compound has single-agent activity, which yields about a 15% response rate for patients with metastatic CRC refractory to 5-FU [Seymour et al. 2007; Cunningham et al. 1998; Rougier et al. 1998,] . In a landmark clinical trial, patients with 5-FU-refractory metastatic CRC were randomly selected to receive either best supportive care or single-agent irinotecan. The results of the trial demonstrated that irinotecan offers an approximate 3-month survival advantage as well as an improvement in quality of life [Cunningham et al. 1998 ]. A second trial in the same secondline patient population found irinotecan superior to infusional 5-FU [Rougier et al. 1998 ]. Following this, three key trials were conducted to test the role of irinotecan in the front-line setting. In the US, a three-arm trial was conducted to compare three treatment regimens: weekly bolus 5 FU/LV (Roswell Park regimen); weekly bolus 5 FU/LV plus irinotecan (IFL); and irinotecan alone [Saltz et al. 2000] . The results of the trial demonstrated a survival improvement of 2 months compared with the bolus 5 FU/LV regimen (14.8 months versus 12.6 months, p ¼ 0.04), as well as a doubling of the response rate to nearly 40% (versus 21%) for patients receiving the three-drug regimen. This study established the three-drug regimen as the then standard of care in the US.
In Europe, two phase III trials were conducted, in which 5-FU was given as an infusion in combination with irinotecan, to form the FOLFIRI regimen. The results demonstrated a similarly significant increase in response rate and time to disease progression for the three-drug regimen [Kohne et al. 2005; Douillard et al. 2000] . However, only the trial reported by Douillard and colleagues [Douillard et al. 2000] demonstrated significant prolongation of overall survival (OS) (17.4 months versus 14.1 months, p ¼ 0.031), likely because of the limited availability of active second-and third-line treatment options, in contrast to the later trial conducted by Koehne and colleagues which conceivably diminished the difference obtained in first-line therapy.
The main side effects of irinotecan are diarrhea, myelosuppression, and alopecia.
Oxaliplatin. Although oxaliplatin has very limited activity in CRC as a single agent, it shows enhanced clinical efficacy in combination with fluoropyrimidines, in particular with infusional 5 FU/LV. In three European phase III trials, combination protocols of infusional 5 FU/LV plus oxaliplatin (biweekly FOLFOX or weekly FUFOX) were compared with 5 FU/LV as firstline therapy for patients with advanced CRC [Grothey et al. 2002; De Gramont et al. 2000; Giacchetti et al. 2000] . In all three studies, a higher antitumor activity was noted for the combination regimens, with response rates of approximately 50% and progression-free survival (PFS) in the range of 89 months. However, this higher efficacy did not translate into a significantly improved OS, most likely because of the availability of active salvage therapies for both treatment arms, which blurred the effects of the first-line chemotherapy on OS in the trials. Of note, the median OS achieved with 5 FU/LV and oxaliplatin was in the range of 17.520 months the longest OS reported in phase III trials for advanced CRC up to that time. Because no OS benefit was achieved in these first-line trials in 2000, the FDA did not approve oxaliplatin for CRC. The FDA approval of oxaliplatin in combination with 5 FU/LV in 2002 was based on the results of a second-line study that showed prolonged PFS and increased response rates compared with infusional 5 FU/LV for patients who experienced disease progression while receiving IFL as first-line therapy [Rothenberg et al. 2003] . It is of note that in this trial the arm with oxaliplatin as single agent, without 5-FU, did not show any relevant tumor activity at all. The key side effect and dose-limiting toxicity of oxaliplatin is neurotoxicity, which comes in two distinct forms: an acute, cold-triggered sensory neuropathy, which is temporary, rapidly reversible, and does not appear to cause structural nerve damage; and a chronic cumulative sensory neurotoxicity, which is related to the cumulative dose of oxaliplatin administered over time and constitutes the dose-limiting side effect of oxaliplatin [Grothey, 2003] .
Comparison of 5-FU-based combination regimens with irinotecan and oxaliplatin With its FDA approval in 2000, IFL had emerged as standard first-line therapy for patients with advanced CRC in the United States.
The encouraging results of trials conducted in Europe using oxaliplatin formed the rationale for the North Central Cancer Treatment Group/Intergroup trial N9741 . This pivotal and practice-changing trial compared FOLFOX and the non-5-FU-containing combination of irinotecan and oxaliplatin (IROX), as well as with standard combination IFL. The results of N9741 clearly demonstrated the superiority of FOLFOX compared with IFL as first-line therapy for CRC regarding response rate (45 versus 31%, p ¼ 0.002), PFS (8.7 versus 6.9 months, p ¼ 0.0014), and OS (19.5 versus 15.0 months, p ¼ 0.0001). The toxicity profile likewise favored FOLFOX compared with IFL with only neurotoxicity being more prevalent for patients receiving the oxaliplatin-based combination. Results for IROX were in-between the two other arms (response rate, 35%; PFS, 6.5 months; OS, 17.4 months), and as such, FOLFOX emerged as the new standard firstline therapy with rapid and widespread adoption in the US. It should be emphasized that N9741 did not directly compare oxaliplatin and irinotecan; rather, it compared two different combination regimens with different 5 FU/LV backbones. The higher efficacy and better tolerability observed with infusional 5 FU/LV may have contributed to the differences in efficacy between IFL and FOLFOX. Two smaller trials comparing FOLFOX and FOLFIRI with the same 5 FU/LV backbone failed to show significant differences in activity [Colucci et al. 2005; Tournigand et al. 2004] . Although the small sample size of these trials might preclude wide-reaching conclusions, the choice between FOLFOX and FOLFIRI in the clinic should mainly be based on the expected side-effect pattern. Because the benefit of second-line therapy in CRC has been well established, patients should receive all active cytotoxic drugs in the course of their therapy to optimize outcome [Grothey et al. 2004] .
Targeted agents
Bevacizumab. An adequate blood supply is necessary for the rapid growth and development of tumors beyond the micrometastatic state of 12 mm in diameter. Vascular endothelial growth factor (VEGF) contributes to tumor growth by stimulating new tumor blood-vessel growth (angiogenesis) and maintaining immature tumor vasculature. VEGF was initially characterized for its ability to induce vascular leakage and permeability (vascular permeability factor) and to induce vascular endothelial proliferation. VEGF is a member of a family of structurally related proteins. These proteins bind to the family of receptors related to VEGF, thereby stimulating various biologic processes. Antibodies directed at VEGF block VEGF interactions with its receptors, thus preventing VEGF signaling through both VEGFR-1 and VEGFR-2 receptors [Hicklin and Ellis, 2005] . Bevacizumab, a recombinant humanized monoclonal antibody to VEGF has demonstrated clinical efficacy for the treatment of metastatic CRC. In a large phase III placebocontrolled trial with 813 patients, irinotecan plus bolus 5 FU/LV (i.e. IFL protocol) was compared with IFL plus bevacizumab (5 mg/kg every 2 weeks) as first-line therapy for advanced CRC [Hurwitz et al. 2004] . The addition of the anti-VEGF antibody led to significantly increased response rate (45 versus 35%, p ¼ 0.0036), PFS (10.6 versus 6.2 months, p < 0.00001), and median OS (20.3 versus 15.6 months, p ¼ 0.00004). This trial was the first phase III validation of an anti-angiogenic agent serving as an effective treatment option in a human malignancy. Subsequently, bevacizumab also has been shown to enhance the efficacy of oxaliplatin-based regimens in first-and second-line settings, as well as in combination with 5 FU/LV alone or with cetuximab in a salvage therapy setting [Saltz et al. 2008; Giantonio et al. 2007; Saltz et al. 2007; Hurwitz and Kabbinavar, 2005; Kabbinavar et al. 2005] . It is important to note that bevacizumab does not appear to have significant single-agent activity in metastatic CRC [Giantonio et al. 2007] . The main side effects observed with bevacizumab consist of hypertension (a class effect of all agents targeting VEGF signaling), bleeding, gastrointestinal perforations (1.52% of patients), as well as arterial thrombotic events in approximately 45% of patients [Grothey, 2006] . In addition to arterial thrombotic events, a recent meta-analysis identified a 33% higher incidence of venous thrombotic events in patients receiving bevacizumab compared with the non-bevacizumab control arm in randomized trials [Nalluri et al. 2008] .Based on its well-documented efficacy and relatively moderate toxicity, bevacizumab has emerged as standard component of first-line chemotherapy for advanced CRC. Several other agents targeting various components of the VEGF-mediated signal transduction cascade have been developed and are in clinical testing.
Anti-epidermal growth factor receptor antibodies. Both monoclonal antibodies against Therapeutic Advances in Medical Oncology 1 (2) the epidermal growth factor receptor (EGFR), cetuximab and panitumumab, have single-agent efficacy in advanced CRC. Two US phase II trials presented in 2001 and 2002 confirmed the activity of cetuximab for the treatment of patients who had experienced disease progression on prior irinotecan-based therapy [Saltz et al. 2004] . The single-agent response rate of approximately 10% noted with cetuximab alone was in the same range as previously noted with FOLFOX in the same setting. A large international randomized phase II trial comparing cetuximab with cetuximab plus irinotecan confirmed the findings with almost identical results [Cunningham et al. 2004] . For patients who experienced progressive disease while receiving irinotecan-based therapy (with approximately two-thirds of patients also refractory to oxaliplatin), cetuximab monotherapy induced responses for approximately 11% of patients. When irinotecan was added, response rate (22.9 versus 10.8%, p ¼ 0.007) and time to progression were significantly increased [4.1 versus 1.5 months, hazard ratio (HR) 0.54, 95% confidence interval (CI) 0.42, 0.71; p < 0.001]. These data served as the basis for the initial approval of cetuximab as a treatment option for patients with metastatic CRC who were pretreated with irinotecan-based regimens.
Single-agent panitumumab was tested against best supportive care in a large international phase III trial in an extensively pretreated population; crossover was optional upon progression [Van Cutsem et al. 2007 ]. Panitumumab demonstrated similar single-agent activity to cetuximab, with an approximate 10% response rate when used as salvage therapy after failure of standard chemotherapy. In comparison with best supportive care, it significantly prolonged PFS (median PFS 8.0 weeks versus 7.3 weeks; HR 0.54, 95% CI 0.440.66; p < 0.0001). OS was not increased, presumably due to the fact that 75% of patients crossed over from best-supportive care to the panitumumab arm. Based on these data, panitumumab was approved as a single-agent salvage therapy option in the US in 2006. A similar lastline trial comparing cetuximab with best supportive care (without crossover) showed almost identical results in terms of response rate and PFS, but also with survival benefit for the cetuximab arm [Jonker et al. 2007] . Both antibodies have been tested as components of first-line therapy in combination with modern chemotherapy regimens, such as FOLFOX and FOLFIRI, the results of which are discussed further below [Bokemeyer et al. 2008; .
The main toxicities of anti-EGFR antibodies are skin rash, hypomagnesemia, diarrhea, and hypersensitivity reactions, which is particularly relevant for the chimeric antibody cetuximab [Grothey, 2006] . Anaphylactic reactions to cetuximab have recently been correlated to the presence of pre-existing serum IgE antibodies to an oligosaccharide, galactose-alpha-1,3-galactose, which is present on the Fab portion of the cetuximab heavy chain [Chung et al. 2008] . These antibodies have been found in up to 21% in individuals from Tennessee who had never been exposed to cetuximab, compared with only 0.6% of individuals from the Boston, MA region [Chung et al. 2008] . The reason for these geographical differences are not known, but it is conceivable that environmental influences with exposure to sensitizing antigens play a role.
Predictive biomarkers for EGFR antibodies in colorectal cancer
Data from various clinical trials and translational studies have now opened the door toward individualized treatment approaches in CRC by identifying patients who are most likely to benefit from antibodies against the EGFR, cetuximab and panitumumab. It increasingly appears that patients with advanced CRC must have tumor with wildtype KRAS and wild-type BRAF in order for EGFR antibodies to be effective (Figure 1 ) [Amado et al. 2008; Artale et al. 2008; Bokemeyer et al. 2008; Di Nicolantonio et al. 2008; Karapetis et al. 2008; Di Fiore et al. 2007; Lievre et al. 2006; Rajagopalan et al. 2002] .
KRAS is a phosphorylated signal transducer that self inactivates via intrinsic guanosine triphosphatase (GTPase) activity [Malumbres and Barbacid, 2003] . It is a homolog of the transforming gene Kirsten rat sarcoma-2 virus. Several KRAS oncogene mutations in CRC mainly in codons 12 and 13 that result in the production of proteins with reduced GTPase activity have been identified. These KRAS mutations are among the most common oncogenic alterations in cancer.
Four points are important to note with regard to KRAS mutations in CRC:
(1) KRAS mutations occur early in the adenoma-carcinoma sequence leading to CRC, which implies that the mutation can be found in all tumor cells derived from the initial malignant clone, in metastases as well as the primary tumor [Kinzler and Vogelstein, 1996] . (2) The determination of KRAS mutations is a yes/no binary decision; a tumor harbors either wild-type or mutated KRAS, no cutoff levels or subjective grades of expression levels have to be considered. (3) The tests for KRAS mutation, regardless of whether or not mutation-specific polymerase chain reaction (PCR) or gene sequencing is being used, are very robust and of high sensitivity and specificity, and can be obtained from formalin-fixed, paraffinembedded tissue. (4) The frequency of KRAS mutations in CRC is about 40%.
More recently, mutated BRAF, encoding a protein downstream of KRAS, has also been correlated to lack of efficacy of EGFR antibodies in CRC [Artale et al. 2008; Di Nicolantonio et al. 2008] . The frequency of BRAF mutations in CRC is about 10%. Since KRAS and BRAF mutations are mutually exclusive [Rajagopalan et al. 2002] , testing for BRAF and KRAS mutations can exclude about 50% of patients with CRC from an ineffective, but potentially harmful (and expensive) therapy with cetuximab and panitumumab. Further predictive biomarkers for the activity of EGFR antibodies in CRC have been identified in retrospective studies, in which the activity of cetuximab was correlated with the maintained expression of phosphatase and tensin homolog (PTEN) and higher levels of the EGFR ligands, amphiregulin and epiregulin [Loupakis et al. 2008; Frattini et al. 2007; Khambata-Ford et al. 2007 ] Future validation of these markers will be important to further refine the patient population best suited to respond to anti EGFR-targeted therapy.
The clinical importance of KRAS mutations as predictors for efficacy of EGFR-targeted agents in CRC was recently highlighted in an analysis of two phase III trials conducted with panitumumab and cetuximab as single-agent salvage therapy in CRC [Amado et al. 2008; Karapetis et al. 2008] Patients with KRAS-mutated cancers did not derive any benefit from EGFR-antibody monotherapy. In contrast, cetuximab almost doubled OS compared to best supportive care in patients with wild-type KRAS CRC (9.5 versus 4.8 months; HR for death, 0.55; 95% CI, 0.41-0.74; p < 0.001) [Karapetis et al. 2008] . In randomized-trial testing, the addition of cetuximab or panitumumab to standard first-line therapy (FOLFIRI or FOLFOX), again only patients with KRAS wild-type tumors benefited from EGFR antibodies [Hecht et al. 2009; Bokemeyer et al. 2008; .
Based on these data, the European MEdicine Agency (EMEA, the European equivalent of the US Food and Drug Administration [FDA]) has approved panitumumab and cetuximab only for use in patients with KRAS wild-type metastatic CRC.
The question if KRAS mutations are solely predictive or also prognostic markers with better outcome for KRAS wild-type CRCs has long been a matter of debate. The most convincing data set in this regard can be found in the phase III salvage therapy trial of cetuximab versus best-supportive care (no crossover!) in which there was no difference in OS for KRAS wild-type or KRAS mutant tumors in the group of patients on best-supportive care [Karapetis et al. 2008] . This clearly suggests that KRAS is a predictive, but not prognostic factor in CRC.
With the proof of efficacy of two biologic therapeutic approaches in CRC, bevacizumab as a VEGF-targeting agent and cetuximab/panitumumab as EGFR antibodies, it appears logical to try and further enhance the efficacy of therapy by combining both approaches. Initial data for the combination of bevacizumab and cetuximab with or without irinotecan in a salvage therapy setting were promising [Saltz et al. 2007] , so that several subsequent clinical trials investigated the combination of standard chemotherapy (FOLFOX, CAPOX, or FOLFIRI) plus bevacizumab with or without either cetuximab or panitumumab. Surprisingly, the addition of an EGFR antibody to the bevacizumab-based combination therapy reduced PFS in the intent-to-treat populations and not even the KRAS wild-type tumor population benefited from the intensified and more toxic therapy [Tol et al. 2009; Hecht et al. 2009; Punt et al. 2008] . In fact, in KRASmutant tumors a detrimental effect was observed when cetuximab or panitumumab was added to bevacizumab-containing chemotherapy. While an explanation for these findings is still elusive, the combination of bevacizumab with EGFR antibodies should not be used in clinical practice outside of clinical trials.
Treatment guidelines
Goal-oriented approach as overarching principle With multiple treatment options available for first-line therapy, it is important to realize that the initial therapeutic step of nonresectable stage IV CRC should be determined by the overall goal of therapy potential cure or palliation. This goal-oriented approach introduces an individualized treatment-strategy based on clinical parameters that nicely complements biomarkerdriven treatment decisions. The selection of regimens and treatment algorithms will depend on how well they meet the demands specified in the goals of therapy. From a clinical perspective, three distinct scenarios and associated treatment goals should be identified:
(1) Patients with limited, but yet unresectable metastatic disease in which tumor shrinkage might allow converting the situation into a potentially curative scenario with resection of all metastases. Consequently, this approach has been termed 'conversion therapy'. It is self evident that those treatment regimens which are associated with high response rates are most likely to meet the demands of this approach [Folprecht et al. 2005] . (2) Patients with significant tumor-related symptoms whose quality of life and perhaps even short-term survival depend on the rapid decrease of tumor burden and symptom control. Again, it is evident that treatment approaches which allow for significant tumor shrinkage are preferable in this palliative situation. (3) The majority of patients in a palliative setting, however, will have no or only mild symptoms from their metastatic disease. In these patients, the pertinent goals of therapy are extending the duration of their lives while maintaining the quality of life as long as possible. These patients will benefit from a careful long-term strategic planning of treatment sequences with mindful attention to toxicities of therapy, a concept defined as 'Continuum of Care' [Goldberg et al. 2007 ].
The Continuum of Care in the palliative therapy of colorectal cancer The concept of Continuum of Care abrogates the idea of distinct lines of therapy in favor of a strategic treatment approach with the goal to eventually expose all patients to all potentially active agents with special attention to prevention and management of toxicities of therapy. Thereby, it ties in duration and intensity of therapy. The concept realizes that we have made little progress in the antitumor activity of first-line therapy as measured by PFS, in spite of the routine use of combination regimens and biologic agents. On the other hand, OS of patients with advanced CRC has gradually increased over the last decade with the availability of more active agents and the sequential use of treatment regimens [Grothey et al. 2004] . This highlights the importance of postprogression therapy to optimize survival. As a side note, this also clearly demonstrates that OS is no longer able to serve as an endpoint for clinical trials of first-line therapy given the significant effect of subsequent therapies on this endpoint. Notably, only phase III trials in any line which did not allow crossover in their study design (a sometimes ethically challenging decision) were able to demonstrate a survival benefit [Jonker et al. 2007; Hurwitz et al. 2004] , whereas trials which were affected by crossover did not [Van Cutsem et al. 2007] . It should also be noted that future advances in the development of predictive markers for treatment response and toxicity will hopefully allow preselection of patient populations which will derive maximum benefit from one or another sequence of treatment steps a concept which is so far largely elusive.
Duration of therapy chemotherapy holidays
With OS in advanced CRC nowadays routinely exceeding 2 years, it is obvious that the same intensity of therapy can hardly be maintained throughout the course of therapy. The Continuum of Care therefore mandates changes in therapy with treatment breaks or phases of less intensive maintenance therapy interspersed with periods of more intensive therapy to control tumor progression. Thereby, chemotherapy holidays conceivably reduce the (cumulative) toxicities of therapy, potentially prevent the unplanned, premature discontinuation of therapy, preserve the ability to administer further phases of therapy, potentially maximize the time on therapy, reduce costs, and could increase quality of life for patients. Several trials have, in the past, tested the influence of chemotherapy holidays on patient outcome, with varying rules when to stop which component of antitumor therapy.
The definition of such 'chemo-holidays' can include (the name of trials utilizing the different definitions is given in parenthesis):
( ).
Agents can be discontinued when: a predefined number of treatment cycles has been reached (OPTIMOX-1, OPTIMOX-2, CONcePT, GISCAD); best response has been achieved (MRC [Maughan et al. 2003] ); or specific toxicities associated with the use of one or more of the agents utilized have emerged.
Restarting of more intensive therapy can occur after: A predefined interval (OPTIMOX-1, CONcePT, GISCAD); relevant tumor progression has been noted (OPTIMOX-2); or after specific toxicities have resolved.
In the era when only 5-FU was available as active agent, the therapy of advanced CRC followed the concept of treatment-to-progression a timeframe which rarely exceeded 6 months. Thus, cumulative toxicities did not play an important role, in particular, when infusional 5-FU regimens were used with their excellent toxicity profile [Kohne et al. 2003 ]. The introduction of irinotecan, and especially oxaliplatin, challenged this concept since cumulative toxicities in the form of myelosuppression and for oxaliplatin cumulative neurotoxicity became factors limiting the duration of therapy. It is of note that in all recent first-line phase III trials with an oxaliplatinbased regimen not disease progression, but factors associated with the long-term tolerability of the regimen were the most common reasons for treatment discontinuation [Grothey, 2003] . The realization that side effect and not loss of antitumor activity commonly limits the duration of oxaliplatin-based first-line therapy has led to the investigation of various strategies to allow for oxaliplatin-free treatment intervals, along the lines of the definitions for chemo-holidays stated before. It is obvious that those treatment strategies need to demonstrate that they can be implemented without compromising the overall efficacy of therapy.
The OPTIMOX-1 and CONcePT (Combined Oxaliplatin Neurotoxicity Prevention Trial) trials tested the same concept of intermittent oxaliplatin administration with a stop of oxaliplatin after a predefined number of cycles followed by a maintenance-therapy phase with infusional 5 FU/LV with (CONcePT) or without (OPTIMOX-1) bevacizumab and subsequent planned reintroduction of oxaliplatin Tournigand et al. 2006] . Both trials clearly showed that the overall toxicities associated with oxaliplatin can be reduced by its intermittent administration without compromising efficacy. In fact, some efficacy parameters favored the intermittent oxaliplatin arm, presumably due to the fact that patients could remain longer on therapy when cumulative toxicities were avoided. These findings highlight the importance of recognizing and pre-empting potential toxicities associated with prolonged palliative therapy to optimize patient benefit.
The concept of complete chemotherapy-free intervals was initially tested by a MRC (Medical Research Council) trial in the United Kingdom which was conducted in the pre-irinotecan and pre-oxaliplatin era, thereby somewhat limiting the generalizability of the findings into current clinical practice [Maughan et al. 2003 ]. In this trial, chemotherapy-free intervals were not associated with a detrimental effect on patient outcome. This was in contrast to findings in the more recent OPTIMOX-2 trial, which suggested a shorter PFS, and more importantly shorter OS for patients who underwent a complete break from FOLFOX without maintenance therapy, although the relatively small sample size of the trial did not allow definitive conclusions [Maindrault-Goebel et al. 2007 ].
Indirect, but clearly not definitive evidence for the importance of treatment continuation until tumor progression comes from the findings of the large phase III trial NO16966, which tested oxaliplatin-based chemotherapy with or without the addition of bevacizumab in first-line CRC [Saltz et al. 2008] . In this trial, patients who were treated until disease progression enjoyed greater benefit from the addition of bevacizumab than patients in whom all active agents were discontinued early.
Several clinical trials are currently underway in Europe (the UK, France, and Spain) which will help to further elucidate the role of chemotherapy holidays on patient outcome and quality of life in the era of modern combination therapy with the routine use of conventional chemotherapy plus targeted agents as the first-line standard of care. Until the results of these studies are available, the default approach in patients with advanced CRC should be to continue some form of anti-tumor therapy until disease progression with mindful attention to treatment toxicities and individual tumor biology. This approach does not preclude the utilization of complete treatment-free intervals in select patients with apparent nonaggressive tumors as component of a long-term oriented treatment strategy.
Duration of therapy treatment beyond progression
The concept of continuing agents from so-called lines-to-lines of therapy is not new. The most important cytotoxic agent in CRC, 5-FU, is routinely carried on from first-to second-line therapy in the form of the FOLFOX-FOLFIRI (or FOLFIRI-FOLFOX) sequence, an approach, which has also been used in various clinical trials [Seymour et al. 2007; Colucci et al. 2005; Tournigand et al. 2004] . It is of note in this context, that the trial leading to the international registration of cetuximab, contained one arm in which irinotecan was continued beyond progression with the subsequent addition of cetuximab and significantly increased efficacy compared to cetuximab alone [Cunningham et al. 2004] . More recently, data from a large observational, nonrandomized cohort study suggested that the continuation of bevacizumab beyond progression is likewise associated with increased patient benefit . However, these findings require confirmation in randomized phase III trials before continuation of bevacizumab beyond tumor can become part of the standard of care in CRC and potentially also in other tumor entities. Clinical trials toward this end are underway in Europe and the United States.
Curative approach in patients with limited hepatic or pulmonary metastasis For the subgroup of patients with recurrent metastatic CRC confined to the liver, the roles of hepatic-directed chemotherapy and hepatic resection have become better defined. There has been only one multicenter evaluation of potentially resectable liver metastases; the results showed an improved survival for patients undergoing resection compared with those who either had unresectable disease or had noncurative resection [Poston et al. 2005] . The survival advantage is clinically significant, with a near doubling of survival to nearly 37 months. When pooling data for all patients who have a hepatic resection, the average 5-year survival rate is approximately 3040%, with a less favorable prognosis for patients with multiple lesions, a short interval between the diagnosis of the primary tumor and recurrence, and presence of stage III disease at the time of initial diagnosis Fong et al. 1999] . Neo-adjuvant chemotherapy can be used to downsize initially unresectable metastases to make them amendable for a surgical approach. It has been shown that the OS of patients who undergo successful neo-adjuvant therapy with subsequent R0 resection of liver metastases approaches the survival of patients with initially resectable metastases [Adam et al. 2004; Bismuth et al. 1996] . Thus, the initial therapeutic approach for a patient with limited metastatic disease should always include consideration of a potentially curative option.
The role of chemotherapy in the potentially curative management of stage IV CRC can be classified in three different categories:
(1) Neo-adjuvant therapy for initially resectable metastases, mainly to obtain prognostic information and to test the chemosensitivity of the tumor. (2) Conversion therapy for initially not, or only borderline resectable metastases to allow for metastasectomy after tumor shrinkage. (3) Adjuvant therapy after curative resection of metastases.
To date, no studies have been conducted to establish the value of neo-adjuvant therapy (versus surgery alone) in patients with resectable liver metastases. A European phase III trial in resectable, liver-limited metastatic CRC randomized 364 patients to either proceed to surgery directly, or receive FOLFOX chemotherapy for 3 months followed by resection, and then again followed by 3 months of FOLFOX [Nordlinger et al. 2008] . Patients meeting the eligibility criteria of the trial who received peri-operative chemotherapy had a significant improvement in 3-year PFS compared to patients in the surgery alone arm (36.2 versus 28.1%; HR 0.77, p ¼ 0.041). By its very design, the study was not able to answer the question if all patients with resectable liver metastasis should receive neo-adjuvant chemotherapy. Any beneficial effects of chemotherapy in this situation will have to be balanced against potential side effects of therapy and in particular against the observed higher surgical morbidity after neo-adjuvant therapy [Nordlinger et al. 2008; Petrelli, 2008] .
The likelihood of conversion therapy to eventually lead to liver resection has been correlated with the overall response rate observed with a specific treatment regimen [Falcone et al. 2007; Folprecht et al. 2005] . Since chemotherapy agents can induce distinct hepatic toxicity which increases with the duration and cumulative dose of therapy, conversion therapy should only be conducted to resectability of the liver metastases, not to best response [Abdalla et al. 2006; Vauthey et al. 2006] .
The data on adjuvant therapy after the resection of hepatic or pulmonary metastasis are limited. In one randomized clinical trial, half of the patients who had successful hepatic resection received both systemic and intrahepatic chemotherapy; the other half received only systemic chemotherapy [Kemeny et al. 1999] . The results demonstrated a survival advantage at 2 years for patients who received the intrahepatic chemotherapy combination. This approach has not gained widespread use worldwide because of its difficult drug-delivery process, its associated hepatic toxicities, and in view of the high activity of modern systemic combination chemotherapy. A pooled analysis of two small trials with combined 278 patients that utilized adjuvant therapy after liver resection and a 5 FU/LV regimen demonstrated a strong trend toward improved outcome with systemic adjuvant chemotherapy in this setting (PFS 27.9 versus 18.8 months, HR ¼ 1.32, p ¼ 0.058) [Mitry et al. 2008] . A recent trial demonstrated that the addition of irinotecan to infusional 5 FU/LV in the adjuvant setting did not improve outcome after liver resection, similar to the findings of lack of efficacy of irinotecan in stage III CRC [Ychou et al. 2008] .
It is important to note that there are substantial data to support disease resection outside of the liver, with the lung being the next most common site for secondary resection.
Conclusion
Maximizing treatment benefit for patients with advanced CRC mandates a goal-oriented approach including consideration of potentially curative options in patients with potentially resectable metastasis. In a purely palliative setting, a strategic planning of treatment sequences following the Continuum of Care concept will evaluate the toxicity of chemotherapy and the tumor biology to individualize therapeutic approaches. Although biomarkers will provide some guidance on which agents are potentially useful in a given setting, in particular with regard to the use of EGFR antibodies, the importance of individualizing therapy based on clinical parameters cannot be overemphasized. Importantly, not every situation encountered in clinical practice will be solvable by referring to definitive clinical trial results evidence-based data, so that the eventual treatment decision will rightfully be based on careful evaluation of the individual patient's situation on the background of personal experience and the extrapolation of data from other clinical scenarios. Ychou, M., Hohenberger, W., Thezenas, S., Navarro, M., Gascon, P., Bokemeyer, C. et al. (2008) Randomized phase III trial comparing infused 5-Fluorouracil/Folinic acid (LV5FU) versus LV5FU+Irinotecan (LV5FU+Iri) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC). (Cpt-Gma-301). ASCO Meeting Abstracts 26: LBA4013.
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